StockData
Nurix Therapeutics, Inc. logo

Nurix Therapeutics, Inc. (NRIX) company profile

NRIXNasdaqPharmaceutical PreparationsFiscal year ends November 30
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Aug 31, 2026Last filing: 10-Q on Oct 13, 2026Score 15/3072% below fair value
$14.73−0.75 (-4.84%)

Close on Nov 16, 2026Market cap $1.61BP/E 6.4Yield 0.00%

About Nurix Therapeutics

Pharmaceutical Preparations, SIC 2834

Nurix Therapeutics, Inc. is a clinical-stage biopharmaceutical company that discovers and develops targeted protein degradation medicines for cancer and inflammatory diseases. Its clinical drug pipeline features bexobrutideg, a Bruton's tyrosine kinase degrader; zelebrudomide, a dual degrader of kinase and transcription factors; and NX-1607, a CBL-B inhibitor. The company also creates preclinical degraders and degrader antibody conjugates. Nurix aims to treat patients with unmet medical needs, while collaborating with biopharmaceutical companies, including Gilead Sciences, Sanofi, and Pfizer, to advance partnered discovery programs.

The company operates clinical studies across multiple regions, enrolling patients at trial sites in the United States, the United Kingdom, and selected European nations. Its collaborative agreements cover research and commercialization options in the United States, while the company retains global rights to its lead clinical assets. The provided text does not mention the location of Nurix's corporate headquarters.

Summary of the business section of Nurix Therapeutics's latest annual report, written by StockData.

Company profile

Company

Legal name
Nurix Therapeutics, Inc.
Founded
2012
Headquarters
Brisbane, CA
Address
1600 Sierra Point Pkwy 94005
Phone
(415) 660-5320
Employees
317, Nov 30, 2025
Industry
Pharmaceutical Preparations
Incorporated in
Delaware
Fiscal year ends
November 30
Auditor
PricewaterhouseCoopers LLP, San Jose, California

Stock & identifiers

Ticker
NRIX
Exchange
Nasdaq
IPO date
Jul 24, 2020
Shares outstanding
109M, Sep 30, 2026
Public float
$807.50M, May 30, 2025
Filer category
Large accelerated filer
SEC CIK
1549595
CUSIP
67080M103
ISIN
US67080M1036
FIGI
BBG00SDJ8M78
Share class FIGI
BBG00SDJ8M87
EIN
27-0838048

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Arthur T. SandsPresident, CEO, Director608,333
Houte Hans vanChief Financial Officer42,745
Christine RingChief Legal Officer4,406
Gwenn HansenChief Scientific Officer123,452
Julia P. GregoryDirector10,750
Edward C. SaltzmanDirector–
Judith A. ReinsdorfDirector–
Roy D. BaynesDirector–
Paul M. SilvaDirector–
Anil KapurDirector–
David L. LaceyDirector33,333
Roger D. DanseyDirector–
Lori Anne KunkelDirector0

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$6.37M-$1.07M$2.35M$61$126
FY2024$5.81M$23.31M$2.02M$77$99
FY2023$4.36M-$913.89K$1.62M$22$82
FY2022$9.42M-$5.02M$4.07M$43$91

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryStock awardsOption awardsIncentive payOtherTotalvs. prior year
Arthur T. Sands
President, Chief Executive Officer and Director
$674.58K–$5.17M$510.00K$23.36K$6.37M+10%
Hans van Houte
Chief Financial Officer
$545.83K$587.22K$861.03K$298.24K$4.18K$2.30M+14%
Gwenn M. Hansen
Chief Scientific Officer
$556.00K$770.82K$861.03K$307.44K$2.84K$2.50M+23%
Christine Ring
Chief Legal Officer and Chief Compliance Officer
$527.50K$587.22K$861.03K$283.82K$3.77K$2.26M+12%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Jul 24, 2020
Offer price
$19.00
Securities offered
11,000,000
Gross proceeds
$209.00M
Exchange
Nasdaq
First trading day
Jul 24, 2020
First-day close
$19.01+0.1%
Lock-up ends (est.)
Jan 20, 2021

“The initial public offering price is $19.00 per share.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of November 30, 2025, we had 317 full-time or part-time employees, of which approximately 38% have earned an M.D.”

Corporate history

Events identified from SEC filings

DateEventDetails
Jul 24, 2020IPOInitial public offering priced (424B4 prospectus)
Jul 20, 2020ListingRegistration of securities on an exchange (Form 8-A)
Sep 18, 2015Name changeName changed from Nurix, Inc. to Nurix Therapeutics, Inc.

See a number that looks wrong?